Inivata raises up to £4m from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation to advance cancer blood tests.
The funding was provided by Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
Inivata is a clinical cancer genomics company that utilises circulating tumour DNA analysis from blood samples to improve cancer testing and treatment.
Inivata has secured up to £4m in a tranched funding round backed by Imperial Innovations, Cambridge Innovation Capital, and Johnson & Johnson Development Corporation. The company develops clinical cancer genomics applications through circulating tumour DNA analysis from routine blood samples.
The capital will support the ongoing development of the technology in Cambridge and its translation into clinical practice for patient benefit.
Investor perspective
"This investment will secure the development of this technology in Cambridge and facilitate its translation into the clinic for the benefit of patients"
Robert Tansley
Cambridge Innovation Capital
Use of funds
- 01Fund research and development
Investors
Imperial Innovations
Robert Tansley
Cambridge Innovation Capital
Johnson & Johnson Development Corporation